Abstract
Using an established corneal stromal cell differentiation model, we manipulated alpha-smooth muscle actin (alpha-SMA) protein expression levels in fibroblasts by treating them with TGF-beta1, bFGF, TGF-beta type I receptor inhibitor (SB-431542), and siRNA against alpha-SMA. The corresponding cell traction forces (CTFs) were determined by cell traction force microscopy. With all these treatments, we found that alpha-SMA is not required for CTF induction, but its expression upregulates CTF. This upregulation involves the modification of stress fibers but does not appear to relate to non-muscle myosin II expression or beta-actin expression. Moreover, there exists a linear relationship between alpha-SMA protein expression level and CTF magnitude. Finally, CTFs were found to vary among a population of myofibroblasts, suggesting that alpha-SMA protein expression levels of individual cells also vary.
Copyright (c) 2006 Wiley-Liss, Inc.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Actins / biosynthesis*
-
Actins / genetics
-
Actins / metabolism
-
Actins / physiology
-
Animals
-
Benzamides / pharmacology
-
Cell Differentiation / drug effects
-
Cell Differentiation / physiology
-
Corneal Stroma / cytology*
-
Corneal Stroma / drug effects
-
Corneal Stroma / metabolism*
-
Dioxoles / pharmacology
-
Fibroblast Growth Factor 2 / pharmacology
-
Mechanotransduction, Cellular
-
Muscle, Smooth / metabolism*
-
Muscle, Smooth / physiology
-
Myosin Type II / biosynthesis
-
Myosin Type II / metabolism
-
RNA, Small Interfering / genetics
-
Rabbits
-
Stress, Mechanical
-
Stromal Cells / cytology
-
Stromal Cells / drug effects
-
Stromal Cells / metabolism
-
Transforming Growth Factor beta1 / pharmacology
Substances
-
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
-
Actins
-
Benzamides
-
Dioxoles
-
RNA, Small Interfering
-
Transforming Growth Factor beta1
-
Fibroblast Growth Factor 2
-
Myosin Type II